Illumina’s Strategic Pivot Into Proteomics Faces Market Skepticism

As its share price continues to struggle, Illumina is making a decisive strategic move by entering the human protein measurement space. The DNA sequencing specialist has launched its “Illumina Protein Prep” solution globally, aiming to capture a significant position within the expanding proteomics industry. This ambitious expansion raises a critical question for investors: can breakthrough technology reverse the company’s persistent downward trend?

This strategic initiative follows the company’s announced acquisition of SomaLogic, scheduled for June 2025. Even before the deal is finalized in the first half of 2026, Illumina is already integrating the target company’s aptamer-based proteomics platform. The underlying message to the market is unambiguous: Illumina intends to be a comprehensive player in biological data, moving far beyond its... Read more...